Emergent Substitution of Fludarabine for Cyclophosphamide Due to Acute Cardiac Toxicity during Conditioning with Successful Engraftment  by Alsaedi, Hawazen Saleh et al.
Figure 1. Results of the Child Health Questionnaire (CHQ)
Figure 2. Results of the Pediatric Outcomes Data Collection Instrument (PODCI)
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chimerism. There was a modest to strong correlation
between the functional and psychosocial domain scores of
the CHQ and PODCI. Furthermore, the parents were overall
satisﬁed with the care received. The multidisciplinary follow-
up setting with experienced specialists in all participating
centers might have positively contributed to this high level of
satisfaction.
Conclusion: The functional health of transplanted MPS IH
patients was signiﬁcantly more affected than the psychoso-
cial health compared to their healthy peers. Assessing the
functional as well as the psychosocial health can play an
important role in the evaluation of outcomes in MPS IH pa-
tients receiving HCT as well as new therapeutic approaches.274
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Cyclophosphamide (CY) is an alkylating agent with potent
antineoplastic, immunosuppressive, and immunomodula-
tory properties. CY induced cardiac toxicity has been docu-
mented with higher doses, including cardiomyopathy and
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239 S209hemorrhagic myocarditis. We present 2 cases of successful
engraftment after emergent substitution of ﬂudarabine (FLU)
for CY due to acute cardiac toxicity. Case 1 is a 6-mo-old
female with 11q23+ AML who underwent MRD BMT in CR1
with a planned preparative regimen of BU/CY. BU adminis-
trationwas completedwith targeted PKs; however, screening
creatine kinaseprior to scheduledCYadministrationonday-5
showed a markedly elevated level of 301 IU/dl with a normal
EKG. Troponin1 level was also very elevated at 0.49 ng/ml.
Fludarabine (FLU) was substituted for CY at 1.3mg/kg/dose
from day -5 through day -2. Neutrophil and platelet engraft-
ment occurred on day +11 and she remains 99% donor 3 yrs
post-BMT. Case 2 is a 3-yr-old female with primary myeloﬁ-
brosis who underwent a 10/10 MUD HSCT with a planned
preparatory regimen of CY/TBI. She received one dose of CYat
60 mg/kg but developed low voltage on her screening EKG
prior to the second dose. CKwas normal. FLUwas substituted
for the remaining dose of CY at 30 mg/m2/dose and she
received the planned 1200 cGy TBI. She had neutrophil
engraftment on day +32 and platelet engraftment on day +96.
She remained 100% donor but unfortunately died 10 months
post-BMT due to GVHD. Both patients had no further cardio-
vascular toxicity other than hypertension. CY induced hem-
orrhagic myocarditis is invariably fatal. Screening tests with
serum CK and EKG may be used to predict early signs of car-
diac toxicity. In the acute setting of cardiac toxicity, FLU offers
an appropriate therapeutic substitution to avoid further car-
diac toxicity and allow successful engraftment.275
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Introduction: Mixed chimerism (MC) and MRD strongly
predict relapse in children with ALL after allo-SCT. Pre-
emptive immunotherapy (IT), e.g. withdrawal of immuno-
suppression (WD-IS) or DLI can prevent impending relapse.
In this study we retrospectively analyzed chimerism and
MRD monitoring and the effect of pre-emptive IT.
Patients: Between January 2005 and July 2014, a total of 89
pts with ALL (pB-ALL, n¼63; T-ALL, n¼20; biphen. ALL, n¼6)
received allo-SCT in our institution. 47 pts were in CR1, 26 pts
in CR2, 15 pts were CR3 and 1 pt CR4 at time of transplant.
Donors were MSD (n¼18), MUD (n¼61) and haploidentical
(n¼10). Conditioning consisted of TBI (12 Gy) and ETO in pts
with a matched donor and FLU, THIO, MEL in haplo pts.
Methods: Chimerism was assessed weekly in peripheral
blood until day 200 and monthly thereafter. Bone marrow
analyses were done at days +30, +60, +90, +180 and +365
post-transplant. Thereby, MRD was assessed in 56 pts,
whereas no diagnostic material was available in 33 pts.
Results: 64/89 pts (72%) showed complete chimerism (CC) in
all follow-up analyses, and 25/89 pts (28%) developed MC.From 56 pts in whom MRD could be assessed, 40 pts
remained MRD negative and 16 developed MRD positivity
after transplantation. IT (WD-IS, n¼12; DLI, n¼14) was
initiated based on chimerism analysis in 22/25 pts with MC,
and was guided by MRD detection in 4 pts. For the total
cohort of pts, pEFS and pOS were 0.67 and 0.77, respectively.
Cumulative incidence (CI) of TRM and relapse (CI-R) were
0.11 and 0.24 for all pts.
Chimerism: pEFS was 0.74 in CC-pts and 0.51 in MC-pts
(p<0.032). 22/25MC-pts received pre-emptive IT resulting in
a pEFS of 0.58. Due to rapid progression IT was not initiated
in 3/25 MC pts. All MC pts without IT relapsed. While CI-TRM
remained low (0.10 for CC resp. 0.12 for MC, p>0.68) in both
groups, CI-R was 0.17 in CC- and 0.41 in MC-pts (p<0.021).
MRD: Pts were grouped according to their highest MRD
value post-transplant in MRD negative, low positive (<10E-
4), and high positive (>10E-4) pts. pEFS and pOS were 0.82
and 0.95 in MRD negative (n¼40), 0.56 and 0.88 in low level
MRD (n¼8), and 0.25 and 0.25 in high level MRD (n¼8)
positive pts (p<0.001). CI-Rwas 0.14 inMRD negative, 0.36 in
MRD low, and 0.75 inMRD high positive pts (p<0.001), while
CI-TRM between these groups remained low (0.05 for MRD
negative, 0.13 for MRD low and 0.00 for MRD high, p>0.55).
Multivariate analysis: Multivariate analysis for pEFS also
indicated that MC and high level MRD were independent
poor prognostic factors (MC, p<0.049, RR 3.16 and high level
MRD, p<0.022, RR 3.99), while remission status before
transplantation, ALL lineage, donor type, graft source, T cell
depletion or sex showed no signiﬁcant inﬂuence.
Conclusion: Our results show that analysis of chimerism and
MRD allow the prediction of impending relapse in virtually
all pts with ALL and that pre-emptive IT can improve
outcome in these pts.276
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Introduction: The optimal timing of Alemtuzumab admin-
istration during RTC regimen is not well studied. Proximal
administration may lead to more in vivo T cell depletion,
decreasing GVHD but potentially increasing graft failure (GF)
and delaying immune reconstitution. Intermediate admin-
istration may improve engraftment but could lead to higher
rates of GVHD. We compared two centers’ experiences
studying the schedule of Alemtuzumab within Busulfan/
Fludarabine RTC regimen.
Methods: Pts21 years old undergoing alloHCT formalignant
and non-malignant conditions using a Busulfan-12.8-16mg/kg
